CORCEPT THERAPEUTICS INC (CORT) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US2183521028

Price
116.23 USD
Market cap
12.56 bn USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

CORCEPT THERAPEUTICS INC financials

Fiscal year2025
Revenue761.41 m USD
Gross profit748.43 m USD
Operating income44.80 m USD
EBIT66.46 m USD
Net income99.65 m USD
Diluted EPS – continuing operations0.82 USD

Full history since 2000, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About CORCEPT THERAPEUTICS INC

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 14.10.2026. Details in the risk notice.

CORCEPT THERAPEUTICS INC stock (CORT): P/E, revenue, dividend | finmetric